P. aeruginosa mucoid exopolysaccharide specific binding peptides
AssigneesThe Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
InventorsGerald Pier, Michael Preston, Lisa Cavacini, Marshall Posner
Life of this patent
Estimating the term…
Abstract
The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
Claims17
1-74. (canceled)
A composition comprising an isolated antibody or antibody fragment that selectively binds to P. aeruginosa mucoid exopolysaccharide (MEP) and comprises at least two MEP-binding CDR amino acid sequences.
Dependencies are inferred from the claim text.